Cancer Research UK’s recently launched strategy has highlighted the need for early diagnosis as one of its four key objectives to improve survival for patients. Read the full strategy here.
CRUK says: “Diagnosing cancer earlier is one of the most powerful ways to improve cancer survival. The chances of successful treatment are much higher for almost all types of cancer it it’s found early.”
CRUK has pledged £20 million a year investment by 2019 into research for early cancer diagnosis. It believes that advanced cancer screening needs to be as precise as possible so people with cancer can be accurately identified at a point when treatment is likely to make the most difference.
CRUK’s vision is to vastly improve survival for all cancer patients and to bring forward the day when all cancers can be cured. Half of cancer patients diagnosed today will survive at least 10 years; CRUK’s aspiration is for three-quarters of people to survive the disease in the next 20 years.
Chris Hodkinson, Abcodia’s COO, said: “This is an excellent strategy and commitment to advancing much needed biomarkers for early cancer diagnosis which will ultimately improve treatment options and survival for patients. Abcodia is committed to achieving the same goals, particularly for those cancers with the lowest survival rates which are difficult to diagnose at an early stage and spread to other parts of the body.”
Abcodia, along with CRUK and Cancer Research Technology, are lead partners in the Early Diagnosis Consortium (EDC). The EDC aims to work with the best companies and academic groups around the world to identify new biomarkers for earlier diagnosis of cancer and improve survival.
Abcodia is also developing its own products. In 2015 it plans to launch ROCA, the world’s first screening test for ovarian cancer. Ovarian cancer is often detected at a late stage when it has spread to other parts of the body, but clinical trials in both the UK and US show promise that ROCA has capability to detect ovarian cancer at early stages where the woman is reporting no symptoms. The final results of the largest trial, UKCTOCS, are expected in 2015.
We are also seeking to work with other global collaborators who share our passion to develop new biomarkers for other cancers, including pancreatic, lung and colorectal cancer, by providing access to a biobank with more than 5 million longitudinal serum samples, believed to be the largest collection of its kind.
Get in touch to find out more about this unique resource and collaboration opportunities, please contact us firstname.lastname@example.org